Quantcast

Latest RIDGEFIELD Stories

2014-07-08 08:30:12

- Findings from Phase II clinical study of investigational compound volasertib include response rate and new overall survival data. RIDGEFIELD, Conn., July 8, 2014 /PRNewswire/ -- Results from a Phase II study that compared volasertib plus low-dose cytarabine (LDAC), a form of chemotherapy, versus LDAC alone in older patients with untreated acute myeloid leukemia (AML) were published today in the American Society of Hematology journal Blood. Volasertib has not been approved by the...

2014-06-26 08:28:27

Idarucizumab being evaluated to specifically reverse the anticoagulant effect of PRADAXA RIDGEFIELD, Conn., June 26, 2014 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to idarucizumab*, an investigational fully humanized antibody fragment, or Fab, being studied as a specific antidote for Pradaxa (dabigatran etexilate mesylate). "Boehringer Ingelheim is pleased that the...

2014-06-20 08:23:38

RIDGEFIELD, Conn., June 20, 2014 /PRNewswire/ -- Boehringer Ingelheim announced today the initiation of a new international study of Pradaxa® (dabigatran etexilate mesylate). The RE-CIRCUIT(TM) trial (Randomized Evaluation of dabigatran etexilate Compared to warfarIn in pulmonaRy vein ablation: assessment of different peri-proCedUral antIcoagulation sTrategies) will evaluate uninterrupted treatment with PRADAXA, compared to warfarin, in patients with paroxysmal or persistent non-valvular...

2014-06-09 08:29:57

· Data for investigational compounds LY2963016, empagliflozin and empagliflozin/linagliptin combination tablet highlight robust alliance pipeline RIDGEFIELD, Conn. and INDIANAPOLIS, June 9, 2014 /PRNewswire/ -- More than 40 posters, abstracts and oral presentations will demonstrate the breadth and depth of the Boehringer Ingelheim (BI) and Eli Lilly and Company (NYSE: LLY) diabetes portfolio at the 74(th) American Diabetes Association (ADA) Scientific Sessions® in San Francisco, June 13-17....

2014-05-30 08:25:01

- 7 total abstracts accepted for afatinib and other compounds from the company's oncology research program RIDGEFIELD, Conn., May 30, 2014 /PRNewswire/ -- Boehringer Ingelheim today announced that new data will be presented from 7 abstracts for Gilotrif® (afatinib) and investigational compounds, including nintedanib and BI 836845, from its oncology pipeline at the 50(th) Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, IL, on May 30 - June 3, 2014. Data include...

2014-05-28 08:31:29

RIDGEFIELD, Conn., May 28, 2014 /PRNewswire/ -- Boehringer Ingelheim (BI) announced today that it has reached a comprehensive settlement of state and federal cases in the U.S. litigation regarding Pradaxa® (dabigatran etexilate mesylate) in the amount of $650 million. "Time and again, the benefits and safety of PRADAXA have been confirmed," said Desiree Ralls-Morrison, senior vice president and general counsel, Boehringer Ingelheim USA Corporation. "BI stands resolutely behind PRADAXA and...

2014-05-27 23:11:49

VA misread signs media would uncover wait-time problems & should have taken corrective action Ridgefield, Connecticut (PRWEB) May 27, 2014 If the Veterans Administration had properly prepared for crisis, it could have fixed the massive wait-time problems that have caused public criticism about some veterans dying during waiting time to see a VA doctor, announced Crisis PR expert Brian Dobson of Dobson Communications, online at http://www.DobsonPR.com. The VA misread signs media would...

2014-05-18 16:20:52

-- Two Phase 3 trials met primary endpoint of reduction in annual rate of lung function decline RIDGEFIELD, Conn., May 18, 2014 /PRNewswire/ -- Boehringer Ingelheim announced the results of its two pivotal Phase 3 INPULSIS(TM) trials (INPULSIS(TM)-1 and -2; NCT01335464 and NCT01335477), which were published online today in the New England Journal of Medicine (NEJM). The INPULSIS(TM) trials evaluated the efficacy and safety of nintedanib, an investigational therapy being studied in people with...

2014-05-14 20:23:28

-- Results from two Phase III studies (LUX-Lung 3 and LUX-Lung 6) add to the body of evidence supporting the importance of first-line treatment with afatinib in patients whose tumors express the EGFR exon 19 deletion mutation RIDGEFIELD, Conn., May 14, 2014 /PRNewswire/ -- Boehringer Ingelheim today announced new overall survival data of two Phase III clinical trials (LUX-Lung 3 and LUX-Lung 6). Patients with advanced non-small cell lung cancer (NSCLC) whose tumors have the most common...

2014-04-30 12:30:17

- First results of the pivotal Phase 3 INPULSIS(TM) trials investigating the efficacy and safety of nintedanib, an investigational compound, in the treatment of idiopathic pulmonary fibrosis (IPF) RIDGEFIELD, Conn., April 30, 2014 /PRNewswire/ -- Boehringer Ingelheim announced today that the first results from two highly anticipated Phase 3 trials in idiopathic pulmonary fibrosis (IPF) and in chronic obstructive pulmonary disease (COPD) will be presented at the 2014 American...


Word of the Day
mundungus
  • A stinking tobacco.
  • Offal; waste animal product; organic matter unfit for consumption.
This word comes from the Spanish 'mondongo,' tripe, entrails.